Ultragenyx to cut 20% of workforce after Wilson disease gene therapy failure
Ultragenyx Therapeutics announced plans to lay off approximately 20% of its employees and discontinue development of its Wilson disease gene therapy GTX-102 following a major setback in Angelman syndrome trials.
